Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma

Takeshi Hara, Hisashi Tsurumi, Naoe Goto, Jun Ichi Kitagawa, Nobuhiro Kanemura, Takeshi Yoshikawa, Senji Kasahara, Hideko Goto, Kenji Fukuno, Toshiki Yamada, Michio Sawada, Ichiro Yasuda, Naoki Katsumura, Takeshi Takahashi, Tsuyoshi Takami, Hisataka Moriwaki

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)

Abstract

Introduction: We previously described the effectiveness of the THP-COP regimen comprising cyclophosphamide, pirarubicin (tetrahydropyranyl adriamycin; THP), vincristine and prednisolone in patients with diffuse large B-cell lymphoma (DLBCL). The anthracycline drug THP was apparently less cardiotoxic than doxorubicin. However, that study was completed before rituximab was introduced into clinical practice. We conducted a phase II study to determine the effectiveness of a regimen incorporating rituximab (R-THP-COP) against DLBCL. Patients: Six to 8 courses of the regimen were administered every 2 weeks in 48 patients who were younger than 70 years. Results: The complete remission rate was 92%, the 3-year overall survival rate was 83% and 3-year progression free survival rate was 74%. No deaths were associated with the treatment regimen. Conclusion: We conclude that R-THP-COP regimen is very effective against DLBCL. The results of our study urge randomized trials of R-CHOP and R-THP-COP among patients with CD20+ DLBCL.

Original languageEnglish
Pages (from-to)65-70
Number of pages6
JournalJournal of Cancer Research and Clinical Oncology
Volume136
Issue number1
DOIs
Publication statusPublished - 01-2010
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma'. Together they form a unique fingerprint.

Cite this